{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T17:28:31Z","timestamp":1793899711342,"version":"4.8.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>To describe demographic, clinical, and neuropsychiatric safety outcomes in a cohort of PD patients treated with LDp\/CDp infusion in a real-world setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively analyzed a database of 77 consecutive PD patients treated with LDp\/CDp at two Italian tertiary referral centers, with a minimum 6-month follow-up. Baseline cognitive, epidemiological, and clinical variables were assessed to determine potential neuropsychiatric adverse event (NAE) risk factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Patients had long disease duration (13.8\u00b16.4\u00a0years) and moderate-to-severe motor burden (MDS\u2013UPDRS III: 34.4\u00b115). Pre-existing cognitive impairment (MCI 41.6%, dementia 7.8%), prior hallucinations (26%), and impulse control disorders (27.3%) were frequent. At 6\u00a0months, mean L-dopa equivalent daily dose increased by ~300\u00a0mg (\n                      <jats:italic>p<\/jats:italic>\n                      &lt;0.001). The dropout rate was 16.9% (13 patients), mainly due to AEs (38.5%), bridging to DBS (23%), or device intolerance (15.4%). New-onset NAEs emerged in 17 patients (22.1%) at a median of 30\u00a0days, predominantly hallucinations (41.2%) and psychosis (29.4%). Most events were efficiently managed via careful infusion rate adjustments and low-dose antipsychotics, achieving resolution or improvement in 82% of cases. Three patients (18%) discontinued therapy due to severe NAEs. Multivariable regression analysis confirmed baseline Frontal Assessment Battery (FAB) score as the primary independent predictor of NAE development (OR 0.707,\n                      <jats:italic>p<\/jats:italic>\n                      =0.010).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>LDp\/CDp infusion is well-tolerated. Although NAEs were more frequent than in pivotal trials, they were largely manageable. Frontal executive dysfunction emerged as a significant risk factor, suggesting specific frontal screening should be routine in candidacy evaluation for cognitively frail patients. Preventive strategies to reduce risk are proposed and discussed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00415-026-14113-4","type":"journal-article","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T03:57:25Z","timestamp":1789963045000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world neuropsychiatric safety profile of foslevodopa\/foscarbidopa infusion in advanced Parkinson's disease"],"prefix":"10.1007","volume":"273","author":[{"given":"Giulia","family":"Lazzeri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Zangaglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Fazio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0218-5251","authenticated-orcid":false,"given":"Elena","family":"Contaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Bonvegna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Regalbuto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Malaspina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianni","family":"Pezzoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice Jacqueline Mariangela","family":"Jelmoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Piazza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Valentino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Magistrelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis Ugo","family":"Isaias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Pisani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,21]]},"reference":[{"key":"14113_CR1","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1212\/WNL.0b013e3181a1d44c","volume":"72","author":"CW Olanow","year":"2009","unstructured":"Olanow CW, Stern MB, Sethi K (2009) The scientific and clinical basis for the treatment of Parkinson disease (2009). Neurology 72:S1-136. https:\/\/doi.org\/10.1212\/WNL.0b013e3181a1d44c","journal-title":"Neurology"},{"key":"14113_CR2","doi-asserted-by":"publisher","first-page":"925","DOI":"10.3233\/JPD-230372","volume":"14","author":"A Demailly","year":"2024","unstructured":"Demailly A, Moreau C, Devos D (2024) Effectiveness of continuous dopaminergic therapies in Parkinson\u2019s disease: a review of L-DOPA pharmacokinetics\/pharmacodynamics. J Parkinsons Dis 14:925\u2013939. https:\/\/doi.org\/10.3233\/JPD-230372","journal-title":"J Parkinsons Dis"},{"key":"14113_CR3","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/ncpneuro0222","volume":"2","author":"CW Olanow","year":"2006","unstructured":"Olanow CW, Obeso JA, Stocchi F (2006) Drug insight: continuous dopaminergic stimulation in the treatment of Parkinson\u2019s disease. Nat Clin Pract Neurol 2:382\u2013392. https:\/\/doi.org\/10.1038\/ncpneuro0222","journal-title":"Nat Clin Pract Neurol"},{"key":"14113_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2025.107354","volume":"139","author":"PA LeWitt","year":"2025","unstructured":"LeWitt PA (2025) Rethinking the role of continuous dopaminergic stimulation in Parkinson disease therapy. Parkinsonism Relat Disord 139:107354. https:\/\/doi.org\/10.1016\/j.parkreldis.2025.107354","journal-title":"Parkinsonism Relat Disord"},{"key":"14113_CR5","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/S1474-4422(18)30239-4","volume":"17","author":"R Katzenschlager","year":"2018","unstructured":"Katzenschlager R, Poewe W, Rascol O et al (2018) Apomorphine subcutaneous infusion in patients with Parkinson\u2019s disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial. Lancet Neurol 17:749\u2013759. https:\/\/doi.org\/10.1016\/S1474-4422(18)30239-4","journal-title":"Lancet Neurol"},{"key":"14113_CR6","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1097\/WCO.0000000000001277","volume":"37","author":"MN Dean","year":"2024","unstructured":"Dean MN, Standaert DG (2024) Levodopa infusion therapies for Parkinson disease. Curr Opin Neurol 37:409\u2013413. https:\/\/doi.org\/10.1097\/WCO.0000000000001277","journal-title":"Curr Opin Neurol"},{"key":"14113_CR7","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.3233\/JPD-212813","volume":"11","author":"M Rosebraugh","year":"2021","unstructured":"Rosebraugh M, Liu W, Neenan M, Facheris MF (2021) Foslevodopa\/foscarbidopa is well tolerated and maintains stable levodopa and carbidopa exposure following subcutaneous infusion. J Parkinsons Dis 11:1695\u20131702. https:\/\/doi.org\/10.3233\/JPD-212813","journal-title":"J Parkinsons Dis"},{"key":"14113_CR8","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/S1474-4422(22)00400-8","volume":"21","author":"MJ Soileau","year":"2022","unstructured":"Soileau MJ, Aldred J, Budur K et al (2022) Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson\u2019s disease: a randomised, double-blind, active-controlled, phase 3 trial. Lancet Neurol 21:1099\u20131109. https:\/\/doi.org\/10.1016\/S1474-4422(22)00400-8","journal-title":"Lancet Neurol"},{"key":"14113_CR9","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1007\/s40120-023-00533-1","volume":"12","author":"J Aldred","year":"2023","unstructured":"Aldred J, Freire-Alvarez E, Amelin AV et al (2023) Continuous subcutaneous foslevodopa\/foscarbidopa in Parkinson\u2019s disease: safety and efficacy results from a 12-month, single-arm, open-label, phase 3 study. Neurol Ther 12:1937\u20131958. https:\/\/doi.org\/10.1007\/s40120-023-00533-1","journal-title":"Neurol Ther"},{"key":"14113_CR10","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/S1474-4422(06)70373-8","volume":"5","author":"KR Chaudhuri","year":"2006","unstructured":"Chaudhuri KR, Healy DG, Schapira AHV, National Institute for Clinical Excellence (2006) Non-motor symptoms of Parkinson\u2019s disease: diagnosis and management. Lancet Neurol 5:235\u2013245. https:\/\/doi.org\/10.1016\/S1474-4422(06)70373-8","journal-title":"Lancet Neurol"},{"key":"14113_CR11","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1002\/mds.27338","volume":"33","author":"HH Fernandez","year":"2018","unstructured":"Fernandez HH, Boyd JT, Fung VSC et al (2018) Long-term safety and efficacy of levodopa-carbidopa intestinal gel in advanced Parkinson\u2019s disease. Mov Disord 33:928\u2013936. https:\/\/doi.org\/10.1002\/mds.27338","journal-title":"Mov Disord"},{"key":"14113_CR12","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1177\/1877718X251344896","volume":"15","author":"SR Potel","year":"2025","unstructured":"Potel SR, Chondrogiorgi M, Gozzi A et al (2025) Twenty-five-year experience with apomorphine pump in Parkinson\u2019s disease: a real-life long-term retrospective tolerance study. J Parkinsons Dis 15:970\u2013981. https:\/\/doi.org\/10.1177\/1877718X251344896","journal-title":"J Parkinsons Dis"},{"key":"14113_CR13","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/mds.26424","volume":"30","author":"RB Postuma","year":"2015","unstructured":"Postuma RB, Berg D, Stern M et al (2015) MDS clinical diagnostic criteria for Parkinson\u2019s disease. Mov Disord 30:1591\u20131601. https:\/\/doi.org\/10.1002\/mds.26424","journal-title":"Mov Disord"},{"key":"14113_CR14","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1080\/87565649109540545","volume":"9","author":"G Measso","year":"1993","unstructured":"Measso G, Cavarzeran F, Zappal\u00e0 G et al (1993) The mini-mental state examination: normative study of an Italian random sample. Dev Neuropsychol 9:77\u201385. https:\/\/doi.org\/10.1080\/87565649109540545","journal-title":"Dev Neuropsychol"},{"key":"14113_CR15","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s10072-014-1921-3","volume":"36","author":"S Conti","year":"2015","unstructured":"Conti S, Bonazzi S, Laiacona M et al (2015) Montreal Cognitive Assessment (MoCA)-Italian version: regression based norms and equivalent scores. Neurol Sci 36:209\u2013214. https:\/\/doi.org\/10.1007\/s10072-014-1921-3","journal-title":"Neurol Sci"},{"key":"14113_CR16","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1007\/s10072-005-0443-4","volume":"26","author":"I Appollonio","year":"2005","unstructured":"Appollonio I, Leone M, Isella V et al (2005) The Frontal Assessment Battery (FAB): normative values in an Italian population sample. Neurol Sci 26:108\u2013116. https:\/\/doi.org\/10.1007\/s10072-005-0443-4","journal-title":"Neurol Sci"},{"key":"14113_CR17","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1002\/mds.24893","volume":"27","author":"I Litvan","year":"2012","unstructured":"Litvan I, Goldman JG, Tr\u00f6ster AI et al (2012) Diagnostic criteria for mild cognitive impairment in Parkinson\u2019s disease: Movement Disorder Society Task Force guidelines. Mov Disord 27:349\u2013356. https:\/\/doi.org\/10.1002\/mds.24893","journal-title":"Mov Disord"},{"key":"14113_CR18","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1002\/mds.21507","volume":"22","author":"M Emre","year":"2007","unstructured":"Emre M, Aarsland D, Brown R et al (2007) Clinical diagnostic criteria for dementia associated with Parkinson\u2019s disease. Mov Disord 22:1689\u20131707. https:\/\/doi.org\/10.1002\/mds.21507","journal-title":"Mov Disord"},{"key":"14113_CR19","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1002\/mdc3.13681","volume":"10","author":"R Cilia","year":"2023","unstructured":"Cilia R, Cereda E, Piatti M (2023) Levodopa equivalent dose of safinamide. Mov Disord Clin Pract 10:625\u2013635. https:\/\/doi.org\/10.1002\/mdc3.13681","journal-title":"Mov Disord Clin Pract"},{"key":"14113_CR20","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1002\/mds.29410","volume":"38","author":"ST Jost","year":"2023","unstructured":"Jost ST, Kaldenbach MA, Antonini A (2023) Levodopa dose equivalency in Parkinson\u2019s disease. Mov Disord 38:1236\u20131252. https:\/\/doi.org\/10.1002\/mds.29410","journal-title":"Mov Disord"},{"key":"14113_CR21","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1002\/mds.23429","volume":"25","author":"CL Tomlinson","year":"2010","unstructured":"Tomlinson CL, Stowe R, Patel S (2010) Systematic review of levodopa dose equivalency reporting in Parkinson\u2019s disease. Mov Disord 25:2649\u20132653. https:\/\/doi.org\/10.1002\/mds.23429","journal-title":"Mov Disord"},{"key":"14113_CR22","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.neurol.2019.07.024","volume":"176","author":"A-S Blaise","year":"2020","unstructured":"Blaise A-S, Baille G, Carri\u00e8re N et al (2020) Safety and effectiveness of levodopa-carbidopa intestinal gel for advanced Parkinson\u2019s disease: a large single-center study. Rev Neurol 176:268\u2013276. https:\/\/doi.org\/10.1016\/j.neurol.2019.07.024","journal-title":"Rev Neurol"},{"key":"14113_CR23","doi-asserted-by":"publisher","first-page":"2164","DOI":"10.1007\/s00415-019-09337-6","volume":"266","author":"L Lopiano","year":"2019","unstructured":"Lopiano L, Modugno N, Marano P et al (2019) Motor and non-motor outcomes in patients with advanced Parkinson\u2019s disease treated with levodopa\/carbidopa intestinal gel: final results of the GREENFIELD observational study. J Neurol 266:2164\u20132176. https:\/\/doi.org\/10.1007\/s00415-019-09337-6","journal-title":"J Neurol"},{"key":"14113_CR24","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.parkreldis.2017.02.020","volume":"38","author":"M Sensi","year":"2017","unstructured":"Sensi M, Cossu G, Mancini F et al (2017) Which patients discontinue? Issues on levodopa\/carbidopa intestinal gel treatment: Italian multicentre survey of 905 patients with long-term follow-up. Parkinsonism Relat Disord 38:90\u201392. https:\/\/doi.org\/10.1016\/j.parkreldis.2017.02.020","journal-title":"Parkinsonism Relat Disord"},{"key":"14113_CR25","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1002\/mdc3.70060","volume":"12","author":"S Broh\u00e9e","year":"2025","unstructured":"Broh\u00e9e S, Roze E, Grabli D et al (2025) Cognitive and psychiatric adverse effects of foslevodopa\/foscarbidopa in patients with Parkinson\u2019s disease. Mov Disord Clin Pract 12:1028\u20131030. https:\/\/doi.org\/10.1002\/mdc3.70060","journal-title":"Mov Disord Clin Pract"},{"key":"14113_CR26","doi-asserted-by":"publisher","DOI":"10.4802\/jmd.25304","author":"C Desjardins","year":"2026","unstructured":"Desjardins C, de Vaulry HS, Salardaine Q et al (2026) Neuropsychiatric and cognitive safety of subcutaneous foslevodopa\/foscarbidopa in advanced Parkinson\u2019s disease: insights from a real-world cohort. JMD. https:\/\/doi.org\/10.4802\/jmd.25304","journal-title":"JMD"},{"key":"14113_CR27","doi-asserted-by":"publisher","DOI":"10.1002\/mdc3.70249","author":"K Rukavina","year":"2025","unstructured":"Rukavina K, Ebersbach G, Gruber D (2025) Foslevodopa\/foscarbidopa continuous subcutaneous infusion in Parkinson\u2019s disease: real-world short-term data on tolerability, infusion rate adjustments and concomitant medication. Mov Disord Clin Pract. https:\/\/doi.org\/10.1002\/mdc3.70249","journal-title":"Mov Disord Clin Pract"},{"key":"14113_CR28","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1136\/jnnp-2015-312283","volume":"87","author":"F Moisan","year":"2016","unstructured":"Moisan F, Kab S, Mohamed F et al (2016) Parkinson disease male-to-female ratios increase with age: French nationwide study and meta-analysis. J Neurol Neurosurg Psychiatry 87:952\u2013957. https:\/\/doi.org\/10.1136\/jnnp-2015-312283","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"14113_CR29","doi-asserted-by":"publisher","first-page":"494","DOI":"10.5603\/pjnns.107127","volume":"59","author":"M To\u015b","year":"2025","unstructured":"To\u015b M, Dymek A, Malkiewicz J et al (2025) New-onset psychotic symptoms following continuous dopaminergic stimulation with subcutaneous foslevodopa\/foscarbidopa. Neurol Neurochir Pol 59:494\u2013496. https:\/\/doi.org\/10.5603\/pjnns.107127","journal-title":"Neurol Neurochir Pol"},{"key":"14113_CR30","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.parkreldis.2017.09.018","volume":"45","author":"A Antonini","year":"2017","unstructured":"Antonini A, Poewe W, Chaudhuri KR et al (2017) Levodopa-carbidopa intestinal gel in advanced Parkinson\u2019s: final results of the GLORIA registry. Parkinsonism Relat Disord 45:13\u201320. https:\/\/doi.org\/10.1016\/j.parkreldis.2017.09.018","journal-title":"Parkinsonism Relat Disord"},{"key":"14113_CR31","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1007\/s00415-018-8803-1","volume":"265","author":"MJ Catalan","year":"2018","unstructured":"Catalan MJ, Molina-Arjona JA, Mir P et al (2018) Improvement of impulse control disorders associated with levodopa-carbidopa intestinal gel treatment in advanced Parkinson\u2019s disease. J Neurol 265:1279\u20131287. https:\/\/doi.org\/10.1007\/s00415-018-8803-1","journal-title":"J Neurol"},{"key":"14113_CR32","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1002\/mds.28596","volume":"36","author":"A Fasano","year":"2021","unstructured":"Fasano A, Gurevich T, Jech R et al (2021) Concomitant medication usage with levodopa-carbidopa intestinal gel: results from the COSMOS study. Mov Disord 36:1853\u20131862. https:\/\/doi.org\/10.1002\/mds.28596","journal-title":"Mov Disord"},{"key":"14113_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2025.108142","author":"A Cocco","year":"2026","unstructured":"Cocco A, Zangaglia R, Belluscio G et al (2026) Initiating foslevodopa infusion in Parkinson disease: a pragmatic study. Parkinsonism Relat Disord. https:\/\/doi.org\/10.1016\/j.parkreldis.2025.108142","journal-title":"Parkinsonism Relat Disord"},{"key":"14113_CR34","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1002\/mdc3.70245","volume":"13","author":"J Aldred","year":"2026","unstructured":"Aldred J, Bouchard M, Mart\u00ednez-Castrillo JC et al (2026) Efficacy and safety of foslevodopa\/foscarbidopa monotherapy in patients with Parkinson\u2019s disease. Mov Disord Clin Pract 13:181\u2013190. https:\/\/doi.org\/10.1002\/mdc3.70245","journal-title":"Mov Disord Clin Pract"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-026-14113-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-026-14113-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-026-14113-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T17:05:51Z","timestamp":1793898351000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-026-14113-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,21]]},"references-count":34,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["14113"],"URL":"https:\/\/doi.org\/10.1007\/s00415-026-14113-4","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,21]]},"assertion":[{"value":"18 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no potential conflicts of interest relevant to this work. For the preceding 12\u00a0months: GL has received speaking honoraria from AbbVie, Zambon, EverPharma, and Bial; IUI received research grants, speaking and consultant honoraria from Medtronic, Boston Scientific, Newronika, and the Fondazione Pezzoli per la Malattia di Parkinson\u2014ETS, and speaking honoraria from AbbVie; AP has received speaker honoraria from Chiesi, UCB\u00a0Pharma, and AbbVie.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki. The study protocol was approved by the relevant Ethics Committees at the participating institutions: for data collected at ASST Gaetano Pini-CTO (Milan), approval was granted by the Comitato Etico Territoriale Lombardia 3 (protocol no. 3499\/23); for patients enrolled at IRCCS Mondino Foundation (Pavia), approval was granted by the Comitato Etico Territoriale Lombardia 6 (approval no. 2025\u20133.11\/303).","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from all participants.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"612"}}